Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yeah, that’s not even funny.
We’ve all got opinions, it doesn’t mean you need to get personal. At this stage, our opinion is equal to theirs and Mr Market’s opinion counts the most. Look at what he’s saying and telling you.
Ignore Mr Market at your Peril
I’m fairly confident the good professor will apologise or not post again… it’s all speculation nothing is fact either positive or negative, but for all he knows I could be going through a severe depression and ridiculing mental health is what can tip ppl over the edge, the professor should be better informed before making personal attacks
Fully agree with you Lambo. If people want to get personal then it’s only right you can say it to someone’s face.
Shares price is pathetic .DISGRACE whats happened here ! A BASKET CASE OF A COMPANY NOW
29th November 2021 - 2:48 pm
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London.
Alex bottle from Imperial college London professor….
Ridiculing people’s mental health online… won’t go down great at the college I’m sure
Hmmm or are you Alex bottle from imperial college London given IMM have worked with them in the past…
Meeting up for a chat is a threat is it? Oh right ok then, no you ridiculed my mental health so I want to discuss that with you, so as I said send me contact info please as I very much doubt your real name is Alex bottlier
Lambo, resorting to personal threats when met with reasoned discourse only highlights the weakness of your argument and your evident ignorance. Instead of turning to aggression, why not engage in constructive dialogue? You just need to inform yourself better before that happens. If you find yourself reacting with hostility when challenged, seeking help for anger management could be beneficial. It's apparent that you're desperate for attention, but addressing that issue elsewhere would be more productive. Remember, healthy and clever debate involves exchanging ideas, not threats.
I discuss the company and speculate what might happen that’s it, to start ridiculing someone’s mental health is out of order so I suggest you either send me an email address or phone number in your next post or I’ll provide you with mine
Just filter him-you will better-I do!
Alex I’d suggest if you want to get personal then I’m happy to give you my phone number and we can meet up, and you can tell me what help I need, let me know asap
Lambo, while speculation is part of investing, it's crucial to base it on informed analysis rather than mere conjecture. ImmuPharma's recent performance doesn't automatically imply an impending placing. Jumping to conclusions without solid evidence is not only unwise but also unproductive. Let's aim for more insightful discussions based on facts and genuine analysis rather than spreading unwarranted pessimism. Btw, while we are waiting for an update, I would suggest you get some help: https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/
They want to bury their heads in the sand, let them.
Incanthera has a commercial deal to sell 25,000 units at £100 each and will be delivering profit and FCF this year.
I know where Tim’s focus is.
DYOR
Vicious comments lol what a wet wipe you are
Alex I will do neither but cheers all the same
It’s also not groundless or ignorant to speculate a placing is in the way, I mean if it wasn’t why don’t the bod come out and say they are well funded given the price is off 50% since the last placing… anyway they will have to prove this is a going concern when they release the final results so we shall see, but the biotech sector is shocking atm and if you need cash you need to take an almighty discount as seen with avct today which is a retail favourite so can you Imagine the terms IMM will need to take
I completely agree with Arnold's comment. It's evident that ImmuPharma is actively progressing towards its goals, despite short-term fluctuations in its share price. Lambo, it's becoming apparent that many investors are growing weary of the repetitive, vicious, and baseless comments that you've been posting regularly. It's time to properly read all RNSs and to either contribute constructively to the discussion or refrain from spreading unnecessary negativity and false information. Let's focus on meaningful dialogue that adds value to our understanding of ImmuPharma's journey and potential. If you are desperate for attention then look elsewhere or look for professional help.
I’m just happy we haven’t new account created today that are now experts on IMM…
.....better.
ab: Thanks for your upbeat reflections. As good as a positive RNS.
Lambo, it's important to remember that the current trajectory of ImmuPharma's share price doesn't always reflect its true value or potential, especially considering the volatility often seen in the AIM market. Short-term market dynamics and speculative trading can heavily influence stock prices, sometimes obscuring the company's long-term outlook.
ImmuPharma's strategic decisions, such as advancing the Phase 3 study for Lupuzor and forming key partnerships with Avion and Simbec-Orion, alongside efforts to reduce operational costs and secure funding, underscore its dedication to success. While short-term fluctuations may raise eyebrows, they don't detract from the fundamental progress or potential of the company, which is why I remain steadfast in my long-term investment in ImmuPharma.
It's essential to look beyond the daily fluctuations and recognize the significant strides ImmuPharma is making in the biotech sector. By focusing on the broader picture and understanding the true drivers of value, we can better appreciate the company's trajectory and its potential for future growth and success instead of making groundless and ignorant comments every day.
" Let's set the record straight: ImmuPharma has strategically streamlined operations to ensure financial sustainability through 2024, as detailed in our recent updates "
well to "set the record straight"...go back and read it again and note the small print !!...in relation to the share price and Landstead contribution !!
Alex are you saying IMM won’t do a fundraise in 2024?
Alexbottlier - you may be right. But how do you explain the current (relentlessly downward) share price trajectory in that case?
It's disappointing to see unfounded negative comments about ImmuPharma, especially when they seem to lack a solid understanding of our current position and future potential. Let's set the record straight: ImmuPharma has strategically streamlined operations to ensure financial sustainability through 2024, as detailed in our recent updates. Moreover, with Simbec-Orion on board and a clear focus on advancing the Phase 3 study for Lupuzor, our trajectory is based on solid, actionable plans, not mere speculation. It's crucial to question the motives behind these ignorant and negative assertions, particularly from individuals not invested in the company. Misleading and malicious comments serve no purpose but to create unwarranted doubt among our genuine investors. Let's stay informed and optimistic about ImmuPharma's path forward and ignore ignorant and pathetic comments.
"The stock market is designed to transfer money from the Active to the Patient." - Warren Buffett
"Be fearful when others are greedy, and be greedy when others are fearful." - Warren Buffett
Agree in this market when you have no cash and need to raise I don’t think any price is a shock these days, be lucky to get it away at 0.5p let’s put it that way imo